Plain Language Summary of the Innovate Study: Ibrutinib Plus Rituximab is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia.
Christian Buske,Alessandra Tedeschi,Judith Trotman,Ramon Garcia-Sanz,David MacDonald,Veronique Leblond,Beatrice Mahe,Charles Herbaux,Jeffrey Matous,Constantine S. Tam,Leonard T. Heffner,Marzia Varettoni,M. Lia Palomba,Chaim Shustik,Efstathios Kastritis,Steven P. Treon,Jerry Ping,Bernhard Hauns,Israel Arango-Hisijara,Meletios A. Dimopoulos Future oncology（2023）
关键词
B-cell lymphoma,ibrutinib,rituximab,Waldenstrom's macroglobulinemia
AI 理解论文
溯源树
样例
